研究実績｜北里大学医学部血液内科学

2024年

Miyazaki T, Tachibana T, Suzuki T, Izumi A, Fujimaki K, Sato S, Tamai Y, Michishita Y, Suzuki T, Ishii R, Hirasawa A, Hashimoto C, Kabasawa N, Inoue Y, Ishiyama T, Yamamoto K, Kanamori H, Tanaka M, Nakajima H.
Pretransplantation Inflammatory and Nutritional Status in Elderly Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Value of C-Reactive Protein-to-Albumin Ratio.
Transplant Cell Ther. 2024;30(4):400 e1- e9.
Mamorita N, Takeuchi A, Kamata H.
An interactive simulator to deepen the understanding of Guyton's venous return curve.
J Physiol Sci. 2024;74(1):21.
Maeda T, Matsuda A, Kanda J, Kawabata H, Ishikawa T, Tohyama K, Kitanaka A, Araseki K, Shimbo K, Hata T, Suzuki T, Kayano H, Usuki K, Shindo-Ueda M, Arima N, Nohgawa M, Ohta A, Chiba S, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Takaori-Kondo A, Mitani K, Japanese National Research Group on Idiopathic Bone Marrow Failure S.
Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry.
Br J Haematol. 2024;204(5):2086-96.
Kogure Y, Handa H, Ito Y, Ri M, Horigome Y, Iino M, Harazaki Y, Kobayashi T, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Shinozaki T, Yoshida T, Mori I, Iida S, Maeda T, Kataoka K.
ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone.
Blood. 2024;143(23):2401-13.
Horigome Y, Suzuki K, Suzuki T.
Daratumumab Treatment for "Truly Frail" Elderly Myeloma Patients.
Life (Basel). 2024;14(3).
Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Maeda T, Yoshida T, Mori I, Shinozaki T, Iida S.
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan.
Annals of hematology. 2024;103(2):475-88.
Arai S, Tachibana T, Izumi A, Takeda T, Tamai Y, Sato S, Hashimoto C, Fujimaki K, Ishii R, Kabasawa N, Hirasawa A, Inoue Y, Tanaka M, Suzuki T, Nakajima H.
WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Int J Hematol. 2024;120(3):337-46.
Suzuki T.
Diagnosis and treatment of aplastic anemia and lower-risk myelodysplastic neoplasms. Rinsho Ketsueki. 2024;65(9):884-91.
Suzuki T.
Current treatment options for lower-risk myelodysplastic neoplasms.
Rinsho Ketsueki. 2024;65(10):1317-26.

2023年

Kanda Y, Usuki K, Inagaki M, Ohta A, Ogasawara Y, Obara N, Kako S, Kurokawa M, Shimada N, Suzuki T, Hama A, Yamaguchi H, Nakao S, Yamazaki H.
Decision analysis of allogeneic bone marrow transplantation versus immunosuppressive therapy for young adult patients with aplastic anemia.
Int J Hematol. 2023;117(5):660-8.
Hirose N, Tachibana T, Izumi A, Sato S, Tadera N, Tamai Y, Kanamori H, Tanaka M, Nakajima H.
Bridging to transplant and post-transplant maintenance therapy with FLT3 inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid leukemia.
Hematology (Amsterdam, Netherlands). 2023;28(1):2220518.
Suzuki T.
Clinical significance of clonal hematopoiesis and disease boundaries in bone marrow failure diseases.
Rinsho Ketsueki. 2023;64(6):474-81.
鈴木隆浩. 輸血後鉄過剰症の病態と治療. 日本輸血細胞治療学会誌. 2023;69(1):51.

2022年

Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group.
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial.
Int J Hematol.2022;116(2):228-238.
Hayama K, Abe Y, Kamata H, Okina S, Murakami Y, Kanoh Y, Suzuki T.
Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution.
Int J Hematol. 2022;115(4):508-514.
Tsutsue S, Suzuki T, Kim H, Crawford B
Real world assessment of myelodysplastic syndrome: Japanese claims data analysis
Future Oncol. 2022;18(1):93-104.
Imawari K, Uojima H, Hayama K, Toshimitsu H, Sanoyama I, Iwasaki S, Wada N, Kubota K, Hidaka H, Nakazawa T, Shibuya A, Suzuki T, Kumamoto Y, Saegusa M.
Splenectomy for Torsion of a Wandering Spleen in a Patient with Myeloproliferative Disease: A Case Report
Intern Med. 2022;61(14):2143-2148.
鈴木隆浩. 骨髄不全症の鑑別と治療. 日本検査血液学会雑誌. 23(1): 83-93, 2022.

2021年

Motohashi T, Kamata H, Hayama K, Michishita Y, Horigome Y, Tadera N, Okina S, Suzuki T.
Changes in estimate glomerular filtration rate associated with long-term tyrosine kinase inhibitor treatment in patinets with chronic myelogenous leukemia.
Kitasato Med J. 2021;51(1):32-41.
Masuzawa M, Yamashita K, Horigome Y, Amoh Y.
Successful treatment of non-AIDS Kaposi's sarcoma with eribulin.
J Dermatol. 2021;48(7):e345-e346.
Nakazato, T, Hagihara, M, Sahara, N, Tamai, Y, Ishii, R, Tamaki, S, Wake, A, Tajika, K, Sakai, R, Kobayashi, T, Hua, J, Inoue, M, Aisa, Y, Fujisawa, S, Miyazaki, K, Irie, S, Tanaka, E, Higashihara, M
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Ann Hematol. 2021;100(11):2745-2754.
Wada N, Uojima H, Satoh T, Okin S, Iwasaki S, Shao X, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K, Hidaka H, Kako M, Kagawa T, Iwakiri K, Horie R, Suzuki T, Koizumi W.
Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease
Dig Dis. 2021;39(3):234-242.

2020年

堀米佑一, 田寺範行, 道下雄介, 本橋知美, 石田　隆, 翁　祖誠, 鎌田浩稔, 宮﨑浩二, 鈴木隆浩.
妊娠第２期に発症した急性白血病.
臨床血液. 61(8): 865-869, 2020.
鈴木隆浩. 鉄代謝と鉄剤不応性鉄欠乏性貧血. 臨床血液. 61(5): 475-483, 2020.
鈴木隆浩. 輸血後鉄過剰症の診療. 臨床血液. 61(9): 1205-1211, 2020.

2019年

Kawabata H, Usuki K, Shindo-Ueda M, Kanda J, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Miyazaki Y, Kurokawa M, Arai S, Mitani K, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.
Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes.
Int J Hematol. 2019;110(5):533-542.
Sakai R, Ohmachi K, Sano F, Watanabe R, Takahashi H, Takasaki H, Tanaka M, Hattori Y, Kimura H, Takimoto M, Tachibana T, Tanaka E, Ishii Y, Ishiyama Y, Hagihara M, Miyazaki K, Yamamoto K, Tomita N, Ando K.
Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a ulticenter phase II study.
Ann Hematol. 2019;98(9):2131-2138.
Ishida T, Ohashi K, Okina C, Ohashi S, Okina S, Miyazaki K, Suzuki T.
Characteristics of palliative home care for patients with hematological tumors compared to those of patients with solid tumors.
Int J Hematol. 2019;110(2):237-243.
Ishida T, Miyazaki K, Okina S, Miyata T, Hayama K, Higashihara M, Suzuki T.
The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants.
Hematology. 2019;24(1):49-51.
鈴木隆浩. 骨髄異形成症候群－診断のポイント－. 日本検査血液学会雑誌. 20(1): 99-109, 2019.

2018年

Ishida T, Akagawa N, Miyata T, Tominaga N, Iizuka T, Higashihara M, Suzuki T, Miyazaki K.
Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia.
Int J Hematol. 2018;107(3):373-377.
Matsuda A, Kawabata H, Tohyama K, Maeda T, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Usuki K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Ohta A, Miyazaki Y, Nakao S, Ozawa K, Arai S, Kurokawa M, Mitani K, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes.
Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study.
Leuk Res. 2018;74:137-43.
Nakashima M, Yamochi T, Watanabe M, Uchimaru K, Utsunomiya A, Higashihara M, Watanabe T, Horie R.
CD30 Characterizes Polylobated Lymphocytes and Disease Progression in HTLV-1-Infected Individuals.
Clin Cancer Res. 2018;24(21):5445-57.
鈴木隆浩. 専門医に紹介すべき貧血－紹介すべきタイミングと鑑別検査.
日本医師会雑誌. 147(4): 713-717, 2018.

2017年

Fujiwara SI, Muroi K, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Ozawa K.
CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia.
Hematology. 22(6):347-353.2017.
Yokoyama M, Ichinoe M, Okina S, Sakurai Y, Nakada N, Yanagisawa N, Jiang SX, Numata Y, Umezawa A, Miyazaki K, Higashihara M, Murakumo Y.
CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.
Int J Hematol. 105(5):614-622.2017.
Ito S, Fujiwara SI, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.
Ann Hematol. 96(5):719-724.2017.
Ishida T, Suzuki S, Lai CY, Yamazaki S, Kakuta S, Iwakura Y, Nojima M, Takeuchi Y, Higashihara M, Nakauchi H, Otsu M.
Pre-Transplantation Blockade of TNF-α-Mediated Oxygen Species Accumulation Protects Hematopoietic Stem Cells.
Stem Cells.35(4):989-1002.2017.
Ikuta K, Hatayama M, Addo L, Toki Y, Sasaki K, Tatsumi Y, Hattori A, Kato A, Kato K, Hayashi H, Suzuki T, Kobune M, Tsutsui M, Gotoh A, Aota Y, Matsuura M, Hamada Y, Tokuda T, Komatsu N, Kohgo Y.
Iron overload patients with unknown etiology from national survey in Japan.
Int J Hematol. 105(3):353-360.2017.
Kamata H, Miyazaki K,Komatsu S，HyunSuk Jung，Roger Craig，Higashihara M,Suzuki T,Ikebe M.
Mutation in the tail region of MYH9 inhibits disassembly ofnonmuscle myosin IIA.
Kitasato Med J. 47: 31-42. 2017.
Ishida T, Yokoyama M,Danbara M, Michishita Y,Horie R, Higashihara M, Miyazaki K.
Successful treatment with ibrutinib of intractable thrombocytopenia associated with recurrent chronic lymphocytic leukemia.
Kitasato Med J . 47: 81-86.2017.
Umino K, Fujiwara SI, Sato K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Hatano K, Okazuka K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement.
Acta Haematol. 137(2):93-99. 2017.
Umino K, Fujiwara SI, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
Leuk Lymphoma. 58(2):316-323. 2017.
Kamata H, Tsukasaki Y, Sakai T, Ikebe R, Wang J, Jeffers A, Boren J, Owens S, Suzuki T, Higashihara M, Idell S, Tucker TA, Ikebe M.
KIF5A transports collagen vesicles of myofibroblasts during pleural fibrosis.
Sci Rep. 4;7(1):4556.2017.

2016年

Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Nakano H, Ashizawa M, Okazuka K, Hatano K, Sato K, Oh I, Fujiwara S, Ohmine K, Suzuki T, Muroi K, Kanda Y.
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Leuk Lymphoma. 57(11):2541-7. 2016.
Ishida T, Takahashi S, Lai CY, Nojima M, Yamamoto R, Takeuchi E, Takeuchi Y, Higashihara M, Nakauchi H, Otsu M.
Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation.
J Exp Med. 22;213(9):1865-80. 2016.
Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Fujiwara S, Okazuka K, Hatano K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kako S, Kanda Y.
Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan.
Ann Hematol.95(9):1513-9.2016.
Suzuki T, Kobayashi H, Kawasaki Y, Okazuka K, Hatano K, Fujiwara S, Oh I, Ohmine K, Kanda Y.
Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations.
Int J Hematol. 104(4):446-53. 2016.